# 5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder

> **NCT05452772** · PHASE2 · RECRUITING · sponsor: **Johns Hopkins University** · enrollment: 66 (estimated)

## Conditions studied

- Tobacco Use Disorder

## Interventions

- **DRUG:** Psilocybin
- **DRUG:** Niacin

## Key facts

- **NCT ID:** NCT05452772
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-01
- **Primary completion:** 2026-12
- **Final completion:** 2027-05
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2025-07-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05452772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05452772, "5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05452772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*